Caxton Corp Satsuma Pharmaceuticals, Inc. Transaction History

Caxton Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $262,462 - $1.94 Million	-68,172 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.01 - $34.69 $8.62 Million - $18.7 Million	-538,148 Reduced 88.76%	68,172 $1.96 Million
Q1 2020 May 15, 2020	SELL	$14.53 - $30.69 $769,101 - $1.62 Million	-52,932 Reduced 8.03%	606,320 $13 Million
Q4 2019 Feb 14, 2020	SELL	$9.32 - $19.68 $1.97 Million - $4.16 Million	-211,568 Reduced 24.3%	659,252 $13 Million
Q3 2019 Nov 14, 2019	BUY	$14.98 - $16.9 $13 Million - $14.7 Million	870,820 New	870,820 $13.1 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.